Enantioselective analysis for L-pidolic acid in ertugliflozin drug substance and drug product by chiral gas chromatography with derivatization.

L-pidolic acid is being used as a coformer for ertugliflozin, a sodium-glucose cotransport 2 inhibitor. A sensitive and rapid two-step achiral derivatization combined with gas chromatography with flame ionization detection or gas chromatography with mass spectroscopic detection was developed and validated for the enantiomeric purity determination of L-pidolic acid in the drug substance and drug product, respectively. The method was used to analyze ertugliflozin drug substance forced degradation samples and showed no racemization of pidolic acid in any of the solid or solution stress samples. Analysis of ertugliflozin drug product stability samples showed no significant levels of D-pidolic acid in the drug product indicating that no significant racemization of pidolic acid occurs in the drug product under normal storage conditions. Based on the data generated, a chiral control for pidolic acid is not necessary for drug substance or drug product, but rather can be controlled in the purchase of L-pidolic acid.

Validation of an enantioselective analysis for (l)-pidolic acid by chiral gas chromatography with derivatization.

A sensitive and rapid analytical method has been validated for the enantiomeric purity determination of l-pidolic acid, a biological lactam and metabolite of glutamic acid commonly found in urine, skin, bones, brain and is available commercially as a food supplement. An efficient, two-step achiral derivatization was implemented which consisted of an alkylation step (using HCl-IPA) followed by an acylation step (using TFAA) of the carboxy and amide functional groups. This allowed detection with high sensitivity using gas chromatography with flame ionization detection. The described procedure employs a CP-Chiralsil-L Val column (25m×0.25mm) at a constant flow rate of 1.5mLmin(-1), a gradient temperature program from 80°C to 160°C and an injector and detector temperature of 250°C. The proposed method was validated according to ICH Q2 standards and included such parameters as specificity, system precision, analyst repeatability, intermediate precision, accuracy, linearity, LOD/LOQ and solution stability.

Method development and validation of arene substituted regioisomers in a pharmaceutical candidate by high temperature GC-FID.

This paper describes the development and validation of a high temperature gas chromatography flame ionization detection (HTGC-FID) method for the purity evaluation of arene substituted regioisomers in a key starting material of a pharmaceutical candidate in Phase 3 studies. The chromatographic conditions of the method employ a (5%-phenyl)-methylpolysiloxane packed column (30m×0.25mm) at a constant flow of 1.0mLmin(-1) with a gradient temperature program from 150°C to 400°C with injector and detector temperatures of 300°C and 340°C, respectively. The calibration curve for the desired product (r=0.9999) was assessed for five points in the range from approximately 1.0µgmL(-1) to 40µgmL(-1). The precision (% RSD) of the method was calculated for six replicate injections and found to be 0.81%. The limits of detection and quantitation were determined to be 0.06 and 0.20µgmL(-1), respectively.

Application of quantitative 19F and 1H NMR for reaction monitoring and in situ yield determinations for an early stage pharmaceutical candidate.

Quantitative NMR spectrometry (qNMR) is an attractive, viable alternative to traditional chromatographic techniques. It is a fast, easy, accurate, and nondestructive technique which allows an analyst to gain quantitative information about a component mixture without the necessity of authentic reference materials, as is the case with most other analytical techniques. This is ideal for the synthesis of active pharmaceutical ingredients (API) that are in the early stages of development where authentic standards of the analytes may not be available. In this paper, the application of (19)F and (1)H qNMR for reaction monitoring and in situ potency determinations will be discussed for an early stage pharmaceutical candidate with several analytical challenges. These challenges include low UV absorption, low ionization, thermal instability, and lack of authentic reference standards. Quantitative NMR provided quick, fit-for-purpose solutions for process development where conventional separation techniques were limited.

Fused-core particles: a practical alternative to sub-2 micron particles.

The benefits of sub-2 micron particle size columns have been widely researched and published. The use of these columns on ultrahigh-pressure liquid chromatography (UHPLC) instrumentation may lead to increased efficiencies and higher throughput. However, these instruments may not be readily available to the pharmaceutical chemist. Within the past year, a practical alternative has been introduced which offers increased efficiencies, but at conventional HPLC pressure limitations. These particles are called fused-core particles and are comprised of a 1.7-micron solid core encompassed by a 0.5-micron porous silica layer (dp = 2.7 micron). The goal for this research was to test these columns for efficiency and robustness utilizing a mixture of Torcetrapib and its relative impurities. Our results indicate that excellent theoretical plates (approximately 14000) were achievable for run times less than 5 min. Compared to the Waters Acquity particles, the fused-core particles achieved approximately 80% of the efficiency but with half the observed backpressure. Our robustness results concluded that these separations were reproducible for at least 500 injections while the % RSD for retention time, theoretical plates, peak asymmetry, and resolution was found to be less than 1%.

The role of UHPLC in pharmaceutical development.

Pharmaceutical separations can be divided into three categories: high throughput, high productivity, and high resolution. These categories contain specific pharmaceutical applications, each of which has distinct separation goals. Traditionally, these goals have been achieved utilizing conventional HPLC with typical column dimensions and particle sizes. The recent introduction of ultra-HPLC (UHPLC) has provided a new potential for method development and analysis. Pharmaceutical chemists must determine the impact of this emerging technology. UHPLC is achieved by using sub-2 microm particle size column packing at increased linear velocities. In order to utilize this technology, mobile phase viscosity must be minimized or the chromatography system must be redesigned to withstand an increased backpressure. Today, there are many commercially available UHPLC systems capable of exceeding conventional pressure limits of 400 bar. The advantage of UHPLC over conventional HPLC is the capability to increase the speed without sacrificing efficiency. In comparison to traditional HPLC, our research showed that UHPLC can decrease run times up to 7 x. In addition, for high resolution applications, UHPLC achieved significant efficiency advantages over traditional HPLC. This paper will evaluate the potential roles for utilizing UHPLC in the pharmaceutical industry.